Principal Securities’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.79M Buy
62,512
+5,585
+10% +$326K 0.06% 319
2025
Q4
$3.07M Buy
56,927
+11,378
+25% +$547K 0.05% 340
2025
Q3
$2.05M Buy
45,549
+1,167
+3% +$54.5K 0.03% 453
2025
Q2
$2.05M Sell
44,382
-551
-1% -$27K 0.04% 404
2025
Q1
$2.54M Buy
44,933
+133
+0.3% +$7.75K 0.06% 298
2024
Q4
$2.53M Buy
44,800
+7,204
+19% +$403K 0.06% 298
2024
Q3
$1.95M Buy
37,596
+9,652
+35% +$453K 0.05% 357
2024
Q2
$1.16M Buy
27,944
+3,171
+13% +$142K 0.03% 445
2024
Q1
$1.34M Buy
24,773
+2,572
+12% +$131K 0.04% 378
2023
Q4
$1.14M Buy
+22,201
New +$1.17M 0.04% 375

Other funds holding BMY

Principal Securities's BMY Position: Q1 2026 in Review

Principal Securities increased its Bristol-Myers Squibb (BMY) stake by 9.8% in Q1 2026, buying an estimated $326K and bringing the position to 62,512 shares worth $3.79M. The position accounts for 0.06% of the portfolio, ranked #319.

Principal Securities first reported a position in BMY in Q4 2023 and has held it in 10 quarters since. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Principal Securities held 62,512 shares of Bristol-Myers Squibb worth $3.79M as of Q1 2026.
  • Principal Securities bought 5,585 Bristol-Myers Squibb shares in Q1 2026, an estimated $326K.
  • Bristol-Myers Squibb made up 0.06% of Principal Securities's portfolio in Q1 2026, its #319 holding.
  • Principal Securities first reported a position in Bristol-Myers Squibb in Q4 2023 and has held it in 10 quarters since.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Principal Securities's 13F filing for Q1 2026, filed 13 May 2026.